"While many committee members appeared to support the change during that discussion, medical experts and patient advocates warned during the public comment period that it would leave infants vulnerable to disease. Some committee members early on Friday raised new concerns about some of the data CDC presented and wanted to extend the recommendations from one month to two to three months. During Thursday's discussion, it was not clear how the one month criterion had been chosen."
"Dr Catherine Troisi, infectious disease epidemiologist at UTHealth Houston, said the US birth-dose policy drove a 97% decline in acute hepatitis B among Americans under 19. The panel did, however, vote unanimously to recommend universal hepatitis B testing for all pregnant women. The meeting will also later consider updates to Covid-19 vaccine guidance. On Thursday, the panel rejected use of the combined measles-mumps-rubella-varicella shot in children under four, citing a small increase in seizure risk, opting instead for separate doses."
A panel of US vaccine advisers appointed by the health secretary chose not to hold a planned vote to delay the first hepatitis B vaccine dose for newborns, citing inconsistencies in the proposed policy. The advisory group discussed changing the decades-old recommendation for a birth dose, which has driven a dramatic decline in hepatitis B rates. Some members signaled support for change, while medical experts and patient advocates warned it could leave infants vulnerable. Committee members questioned CDC data and proposed extending the recommended delay to two or three months. The panel unanimously recommended universal hepatitis B testing for pregnant women and considered Covid-19 guidance updates, while rejecting the combined MMRV shot for children under four due to seizure risk.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]